Durysta (bimatoprost)
- Region
- 🇪🇺 EU
- Active substance
- bimatoprost
- Company
- AbbVie Deutschland GmbH & Co. KG
- Status
- Application withdrawn
- Therapeutic area
- Glaucoma, Open-Angle; Ocular Hypertension
- Application
- EMEA/H/C/005916
- ATC
- S01EE03
- Official record
- www.ema.europa.eu
Indication
Indicated for the reduction of intraocular pressure (IOP) in adults with open angle glaucoma (OAG) or ocular hypertension (OHT) who are unsuitable for topical IOP-lowering medications.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Lumigan Authorised · AbbVie Deutschland GmbH & Co. KG
- 🇪🇺 Ganfort Authorised · AbbVie Deutschland GmbH & Co. KG
Follow Durysta
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.